Clinical Trial Update: A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A pharmacokinetic and pharmacodynamic study comparing HLX01 and Rituximab in CD20-positive B-cell lymphoma completed Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• HLX01 (null)
• Rituximab (rituximab)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: B-cell Non Hodgkin's Lymphoma | Phase 1, Phase 2 | Status: COMPLETED